Monterey Bio Acquisition Co. (NASDAQ:MTRY) Short Interest Down 44.4% in March

Monterey Bio Acquisition Co. (NASDAQ:MTRY – Get Rating) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 1,000 shares, a decrease of 44.4% from the March 15th total of 1,800 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 13,900 shares, the days-to-cover ratio is presently 0.1 days.

Shares of MTRY remained flat at $$9.98 during trading hours on Friday. Monterey Bio Acquisition has a twelve month low of $9.85 and a twelve month high of $9.98. The company has a 50-day moving average of $9.94.

Several institutional investors and hedge funds have recently bought and sold shares of MTRY. Geode Capital Management LLC acquired a new stake in shares of Monterey Bio Acquisition during the fourth quarter worth $133,000. Walleye Trading LLC acquired a new stake in shares of Monterey Bio Acquisition during the fourth quarter worth $296,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Monterey Bio Acquisition during the fourth quarter worth $326,000. Walleye Capital LLC acquired a new stake in shares of Monterey Bio Acquisition during the fourth quarter worth $493,000. Finally, MMCAP International Inc. SPC acquired a new stake in Monterey Bio Acquisition in the fourth quarter worth $1,231,000. Institutional investors own 12.02% of the company’s stock.

About Monterey Bio Acquisition (Get Rating)

Monterey Bio Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to acquire businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp.

Further Reading